Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 · INO-5151

Vaccine (DNA plasmid) · Immune activation, directed at Prostate-specific antigen (KLK3) and Prostate-specific membrane antigen · developed by INOVIO PHARMACEUTICALS

Phase 1 Most advanced trial (none active)

INO Developer

1 Registered trials

What is DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150?

INO-5151 is a DNA plasmid vaccine encoding interleukin-12 and expressing prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) epitopes. It is administered intramuscularly and is being studied in metastatic castration-resistant prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: INO-5151
Drug type: Vaccine (DNA plasmid)
Targets: Prostate-specific antigen (KLK3) (antigen), Prostate-specific membrane antigen (antigen)
Mechanism: Immune activation, directed at Prostate-specific antigen (KLK3) and Prostate-specific membrane antigen
Pathways: immune_activation
Therapy area: Oncology
Developer: INOVIO PHARMACEUTICALS (INO)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03835533	Phase 1	Metastatic Castration-resistant Prostate Cancer	Completed	INO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Castration-resistant Prostate Cancer

More from INOVIO PHARMACEUTICALS

INO-1400 Phase 1 INO-1401 Phase 1 INO-1800 Phase 1 INO-3106 Phase 1 INO-3107 Phase 1/2 INO-3401 Phase 1 INO-4201 Phase 1 INO-4202 Phase 1 INO-4212 Phase 1 INO-4500 Phase 1 INO-4700 Phase 2 INO-5401 Phase 1/2

Sources

ClinicalTrials.gov NCT03835533

Updated Oct 3, 2026. Something wrong or missing? Report it on the INO page.

Follow INO, the company behind DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150

See INO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INO catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z